natgillin/translations-raw huggingface dataset:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING INNER CARTON (WITHOUT BLUE BOX - MULTIPACK ONLY) - 75 mg 
NOTRANJA ŠKATLA (BREZ MODREGA OKENCA - SAMO VELIKO PAKIRANJE)75 mg
- severe constipation. 
- občutek napihnjenosti;
- The active substance is eluxadoline. 
- Učinkovina je eluksadolin.
The film-coated tablets are modified capsule-shaped, pale yellow to light-tan and debossed with ‘FX75' on one side. 
Filmsko obložene tablete so bledo rumene do svetlo rjave barve, v obliki modificirane kapsule, z vtisnjeno oznako »FX75« na eni strani.
- if you have, or have had, disease or dysfunction of the sphincter of Oddi (a small round muscle in your upper belly that controls the flow of bile and pancreatic fluids into your upper intestine); - if you have liver disease with decreased liver function; - if you have had constipation for a while or if constipation is the main symptom of your IBS 
- če imate bolezen jeter z zmanjšanim delovanjem jeter; - če ste bili dalj časa zaprti ali če je zaprtost glavni simptom vašega sindroma razdražljivega črevesa (kar se imenuje »sindrom razdražljivega črevesa z zaprtostjo« [IBS-C]); - če imate ali obstaja možnost, da imate zaporo v črevesju; - če jemljete zdravila, ki lahko povečajo raven koncentracije eluksadolina v krvi (t. i. zaviralci
EU/1/16/1126/006 168 film-coated tablets (3 packs of 56) 
EU/1/16/1126/006 168 filmsko obloženih tablet (3 pakiranja po 56)
The absorption of eluxadoline was rapid under fasting conditions, with a median Tmax value of 2 hours. 
s srednjo vrednostjo Tmax 2 uri.
EU/1/16/1126/005 168 film-coated tablets (3 packs of 56) 
EU/1/16/1126/005 168 filmsko obloženih tablet (3 pakiranja po 56)
PARTICULARS TO APPEAR ON THE OUTER PACKAGING INNER CARTON (WITHOUT BLUE BOX - MULTIPACK ONLY) - 100 mg 
NOTRANJA ŠKATLA (BREZ MODREGA OKENCA - SAMO VELIKO PAKIRANJE)100 mg
Stop taking Truberzi, and seek medical attention immediately if you have new or worsening stomach pain, with or without nausea and vomiting, while taking Truberzi. 
Če se med jemanjem zdravila Truberzi pojavi ali poslabša bolečina v trebuhu, s siljenjem na bruhanje in bruhanjem ali brez njiju, prenehajte jemati zdravilo Truberzi in takoj poiščite zdravniško pomoč.
Adequate Relief Response 
Odziv z ustreznim olajšanjem simptomov
Sphincter of Oddi spasm 
Spazem Oddijevega sfinktra
The film-coated tablets are modified capsule-shaped, pink-orange to peach and debossed with ‘FX100' on one side. 
Filmsko obložene tablete so rožnato oranžne do breskove barve, v obliki modificirane kapsule, z vtisnjeno oznako »FX100« na eni strani.
• Known or suspected biliary tree and/or pancreatic duct obstruction (e.g. gallstones, tumour, periampullary duodenal diverticulum) or sphincter of Oddi disease or dysfunction. 
tumor, periampularni duodenalni divertikel) ali bolezen ali nepravilno delovanje Oddijevega sfinktra.
Effect of OATP1B1 transporter function variability on plasma levels The plasma levels in patients with a genetic predisposition for poor function of OATP1B1 transporter are increased, and in these patients a higher rate of adverse events, especially with regard to gastrointestinal events, as well as CNS effects might be expected (see section 5.2). 
OATP1B1 so zvišane in pri teh bolnikih se lahko pričakuje več neželenih učinkov, zlasti učinkov na prebavila in osrednje živčevje (glejte poglavje 5.2).
Rates of severe constipation were less than 1% in patients receiving 75 mg and 100 mg eluxadoline and there were no serious complications of constipation related to eluxadoline use in pivotal studies. 
Pogostnost hude zaprtosti pri bolnikih, ki so prejemali 75 mg in 100 mg eluksadolina, je bila manj kot
Iron oxide red (E172). 
smukec (E553b), rumeni železov oksid (E172), rdeči železov oksid (E172).
Film-coated tablets 56 tablets. 
56 tablet.
There is an increased risk of pancreatitis with or without sphincter of Oddi spasm (see section 4.3) in patients taking eluxadoline. 
Pri bolnikih, ki jemljejo eluksadolin obstaja zvečano tveganje za pankreatitis s spazmom Oddijevega sfinktra ali brez (glejte poglavje 4.3).
Therefore, in this population, the 75 mg dose twice daily can be used. 
Zato se pri tej populaciji lahko uporablja odmerek 75 mg dvakrat dnevno (glejte poglavji 4.2 in 4.4).
Polyvinyl alcohol (E1203); 
• filmska obloga: polivinilalkohol (E1203), titanov dioksid (E171), makrogol 3350
Gastric lavage or charcoal administration should be considered. 
Razmisliti je treba o izpiranju želodca ali dajanju aktivnega oglja.
Caution should be exercised when administering eluxadoline in IBS patients whose bowel habits vary over time. 
Pri bolnikih s sindromom razdražljivega črevesa, pri katerih se vzorec odvajanja blata spreminja skozi čas, je treba eluksadolin uporabljati previdno.
There is a potential for increased risk of somnolence and sedation when taking eluxadoline (see section 4.8) in patients who may experience increased plasma levels, such as in patients with a genetic predisposition for poor function of OATP1B1 transporter. 
Pri bolnikih, ki imajo zvišane plazemske koncentracije, kot so bolniki z gensko nagnjenostjo k slabemu delovanju prenašalca OATP1B1, je tveganje za zaspanost in sedacijo med zdravljenjem z eluksadolinom lahko povečano (glejte poglavje 4.8).
- if you are allergic to eluxadoline or any of the other ingredients of this medicine (listed in section 6); - if you have, or have had, pancreatitis (inflammation of the pancreas); - if you don't have a gallbladder by birth or your gallbladder has been surgically removed; - if you have, or have had, problems with alcohol abuse, alcohol addiction, or if you drink alcohol; - if you have, or have had, any blockage in your gallbladder, bile ducts, or pancreas (such as gallstones, tumour, duodenal diverticulum); 
- če ste alergični na eluksadolin ali katero koli sestavino tega zdravila (navedeno v poglavju 6); - če imate ali ste imeli pankreatitis (vnetje trebušne slinavke);
0.5 ml (10 µg/ml) 1 vial + 1 syringe + 1 needle 
1 viala + 1 injekcijska brizga + 1 igla
10 pre-filled syringes without needle 
10 napolnjenih injekcijskih brizg brez igle
Route of Administration 
Pot Uporabe
can be given to the following groups of patients: 
se lahko daje naslednjim skupinam bolnikov:
is one 75 mg tablet once a day, taken with or without food. 
je ena 75-miligramska tableta enkrat na dan, vzeta s hrano ali brez nje.
can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
be given marketing authorisation. 
odobri dovoljenje za promet.
It is available as pink, round tablets (75 mg). 
Na voljo je v obliki rožnatih, okroglih tablet (75 mg).
The European Commission granted a marketing authorisation valid throughout the EU for Zopya on 21 September 2009. 
Evropska komisija je dovoljenje za promet z zdravilom Zopya, veljavno po vsej Evropski uniji, odobrila dne 21. septembra 2009.
can be started between seven days and six months after the stroke; 
se lahko začne jemati od sedem dni po napadu do šest mesecev po njem;
is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Plavix.
Previously known as Zopya. 
Zdravilo prej znano pod imenom Zopya.
is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries). 
se uporablja pri odraslih za preprečevanje aterotrombotičnih dogodkov (težav, ki jih povzročajo krvni strdki in otrdelost arterij).
is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine. 
generično zdravilo in je biološko enakovredno referenčnemu zdravilu, velja, da so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel Krka d.d. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Clopidogrel Krka d.d., na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
• patients with peripheral arterial disease (problems with blood flow in the arteries). 
• bolnikom s periferno arterijsko boleznijo (težavami s pretokom krvi v krvnih žilah).
is a medicine that contains the active substance clopidogrel. 
je zdravilo, ki vsebuje zdravilno učinkovino klopidogrel.
is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix. 
generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Plavix.
can be started between a few days and 35 days after the attack; 
Zdravilo Clopidogrel Krka d.d se lahko začne jemati od nekaj dni po napadu do 35 dni po njem;
This is a summary of the European public assessment report (EPAR) for Clopidogrel Krka d.d. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Clopidogrel Krka d.d.
For more information about treatment with Clopidogrel Krka d.d., read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The CHMP concluded that, in accordance with EU requirements, Clopidogrel Krka d.d. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Clopidogrel Krka d.d.
What are the benefits and risks of Clopidogrel Krka d.d. 
Kakšne so koristi in tveganja, povezani z zdravilom Clopidogrel Krka d.d.
been approved? 
odobreno?
The active substance in Clopidogrel Krka d.d., clopidogrel, is an inhibitor of platelet aggregation. 
Zdravilna učinkovina v zdravilu Clopidogrel Krka d.d., klopidogrel, je zaviralec agregacije trombocitov.
has been shown to have comparable quality and to be bioequivalent to Plavix. 
primerljivo raven kakovosti kot zdravilo Plavix ter da mu je biološko enakovredno.
The Committee recommended that Clopidogrel Krka d.d. 
Odbor je priporočil, da se za zdravilo Clopidogrel Krka d.d.
The name of the medicine was changed to Clopidogrel Krka d.d. 
Ime zdravila je bilo 18. maja 2011 spremenjeno v Clopidogrel Krka d.d.
Other information about Clopidogrel Krka d.d. 
Druge informacije o zdravilu Clopidogrel Krka d.d.
The standard dose of Clopidogrel Krka d.d. 
Običajni odmerek zdravila Clopidogrel Krka d.d.
How does Clopidogrel Krka d.d. 
Kako se zdravilo Clopidogrel Krka d.d.
Why has Clopidogrel Krka d.d. 
Zakaj je bilo zdravilo Clopidogrel Krka d.d.
What is Clopidogrel Krka d.d. 
Kaj je zdravilo Clopidogrel Krka d.d.
How is Clopidogrel Krka d.d. 
Kako je bilo zdravilo Clopidogrel Krka d.d.
These effects have been seen frequently, and are sometimes severe. 
Te učinke so opažali pogosto in so včasih hudi.
The frequencies are provided according to the following convention: 
Pogostnosti so opredeljene po naslednji konvenciji:
These results, though not mature, constituted the protocol defined final analysis. 
Ti rezultati, ki sicer še niso bili zreli, pa so sestavljali s protokolom opredeljeno končno analizo.
Three cases were poorly documented and were excluded from the assessment. 
Trije primeri niso bili zadostno dokumentirani, zato so bili izločeni iz ocene.
* Measured at the end of a 30-minute infusion 
* izmerjeno na koncu 30-minutne infuzije
Wait an additional week 
Počakajte še en teden
These effects may occur early on in treatment. 
Ti učinki se lahko pojavijo zgodaj med zdravljenjem.
20 months. 
20 mesecev
Lagoas Park, Edifício 9 
Lagoas Park, Edificio 9
The following information is intended for medical or healthcare professionals only (see section 3): 
Naslednje informacije so namenjene samo zdravstvenemu osebju (glejte poglavje 3):
Reduce next dose by 25%. 
Zmanjšajte naslednji odmerek za 25%.
Myelosuppression was mostly mild or moderate and manageable. 
Mielosupresija je bila večinoma blaga ali zmerna in obvladljiva.
Patients and doctors must be aware of this higher incidence and take action as appropriate. 
Bolniki in zdravniki se morajo tega zavedati in ustrezno ukrepati.
The overall incidence of PPE reported was 44.0%-46.1%. 
Splošna incidenca PPE je bila 44,0 do 46,1%.
The application of ice over the site of extravasation for approximately 30 minutes may be helpful in alleviating the local reaction. 
Približno 30-minutno polaganje ledu na mesto ekstravazacije lahko pomaga ublažiti lokalno reakcijo.
If you are allergic to peanut or soya, do not use this medicine. 
Če ste alergični na arašide ali sojo, ne uporabljajte tega zdravila.
Day 4 dosing of both medicinal products may be delayed up to 48 hours as medically necessary. 
Dajanje obeh zdravil na 4. dan se lahko odloži do 48 ur, če je to medicinsko potrebno.
Very rare 
redki zelo redki
The dose is repeated every 2 to 3 weeks for 2-3 months, then as often as necessary to maintain an improvement in your condition. 
Odmerek je treba ponavljati na vsaka 2 do 3 tedne skupaj 2 do 3 mesece, potem pa tako pogosto, kot je treba, da se ohrani izboljšanje vašega stanja.
Depending on the dose and indication, this may take from 30 minutes to more than one hour (i.e., 90 minutes). 
Odvisno od odmerka in indikacije lahko infuzija traja od 30 minut do več kot eno uro (npr. 90 minut).
If you are unsure about what treatments you have received or any illnesses you have had, discuss these with your doctor. 
Če niste prepričani, kakšna zdravila ste prejemali ali katere bolezni ste imeli, se o tem pogovorite s svojim zdravnikom.
< 1/10,000 including isolated reports 
< 1/10.000, vključno s posameznimi primeri
Continue treatment as needed to maintain a therapeutic response. 
Zdravljenje nadaljujte, kolikor dolgo je potrebno za ohranitev terapevtskega odziva.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in v vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih
3) and extensive mucocutaneous or visceral disease. 
3) in razširjeno mukokutano ali visceralno boleznijo.
However, the response was not life-threatening and the dogs recovered quickly upon discontinuation of treatment. 
Vendar odziv ni bil smrtno nevaren in psi so si po prekinitvi zdravljenja hitro opomogli.
It is because of the potential changes in your blood cells that you will have regular blood tests. 
Prav zaradi možnosti, da pride do spremembe števila krvnih celic v vaši krvi, boste imeli redne krvne preiskave.
The average duration of the most common severe (grade 3/4) events for both groups was 30 days or less. 
Povprečno trajanje najpogostejših hudih neželenih učinkov (3. do 4. stopnja) pri obeh skupinah je bilo 30 dni ali manj.
After dilution: 
Po razredčenju:
not previously reported in clinical trials 
ki še niso bili poročani v kliničnih preskušanjih
Paediatric population The experience in children is limited. 
Izkušnje pri otrocih so omejene.
PPE infrequently resulted in permanent treatment discontinuation (3.7%-7.0%). 
PPE je redko povzročila dokončno ukinitev zdravila (3,7 do 7,0%).
Among the seven cases reviewed, the causality was stated as probable in 4 cases and possible in 1 case. 
Med sedmimi pregledanimi primeri, je bila pri 4 primerih ugotovljena verjetna vzročna povezanost in pri 1 primeru možna vzročna povezanost.
From a microbiological point of view, the product should be used immediately. 
Z mikrobiološkega stališča pa je treba zdravilo uporabiti takoj.
5% of the total dose should be infused slowly over the first 15 minutes. 
5% celotnega odmerka infundirajte počasi v prvih 15 minutah.
The exact mechanism of the antitumour activity of doxorubicin is not known. 
Natančen mehanizem protitumorskega delovanja doksorubicina ni znan.
These effects were mostly mild, with severe (grade 3) cases reported in 17%-19.5%. 
Ti učinki so bili večinoma blagi, o hujših primerih (3. stopnje) pa so poročali v 17 do 19,5% primerov.
Pegylated placebo liposomes are neither mutagenic nor genotoxic. 
Pegilirani placebo liposomi niso ne mutageni ne genotoksični.
In severe cases, these effects may interfere with certain daily activities, and may last for 4 weeks or longer before resolving completely. 
V hujših primerih lahko ti učinki motijo določene vsakodnevne dejavnosti in lahko trajajo kar 4 tedne ali celo dlje, preden popolnoma minejo.
A protocol-defined interim analysis (based on 249 TTP events) triggered early study termination for efficacy. 
S protokolom določena vmesna analiza (na osnovi 249 TTP dogodkov) je vodila do predčasne prekinitve študije kar zadeva ugotavljanje učinkovitosti.
Pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine. 
Nosečnost in dojenje Posvetujte se z zdravnikom ali farmacevtom, preden vzamete katero koli zdravilo.
Grade 3 PPE was reported in 5% of patients. 
O PPE 3. stopnje so poročali pri 5% bolnikov,
The toxicity grading in these tables is based on the National Cancer Institute Common Toxicity Criteria (NCI-CTC). 
Stopnja toksičnosti, navedena v teh preglednicah, temelji na merilih NCI-CTC (National Cancer Institute Common Toxicity Criteria).
In all patients, infusion-associated reactions occurred primarily during the first infusion. 
Pri vseh bolnikih so se infuzijske reakcije pojavile predvsem med prvo infuzijo.
The final analysis for overall survival (OS) performed after a median follow-up of 8.6 years showed no significant difference in OS between the two treatment arms. 
Končna analiza celokupnega preživetja (OS) po medianem spremljanju bolnikov 8,6 let ni pokazala pomembne razlike v OS med obema skupinama zdravljenja.
The risk of low blood counts and infections was similarly low in breast cancer studies. 
Tveganje za premajhno število krvnih celic in pojav okužb je bilo podobno majhno tudi v raziskavah raka dojk.
Fertility The effect of doxorubicin hydrochloride on human fertility has not been evaluated (see section 5.3). 
Plodnost Učinka doksorubicinijevega klorida na plodnost pri človeku niso ocenjevali (glejte poglavje 5.3).
In this case, the dose interval may be extended by 1-2 weeks or the dose reduced (see section 4.2). 
V tem primeru lahko razmik med odmerki podaljšate za 1 do 2 tedna ali pa zmanjšate odmerek zdravila (glejte poglavje 4.2).
 1/100 and < 1/10 
 1/100 in < 1/10
Caution must be observed in patients who have received other anthracyclines. 
Previdnost je potrebna tudi pri bolnikih, ki so prejemali druge antracikline.
Other symptoms of Kaposi's sarcoma, such as swelling around the tumour, may also improve or disappear. 
Tudi drugi simptomi Kaposijevega sarkoma, npr. otekanje okrog tumorja, se lahko izboljšajo ali izginejo.
No grade 4 PPE was reported. 
primerov s PPE 4. stopnje pa ni bilo.
In very rare cases, seizures (convulsions) have occurred. 
V zelo redkih primerih so se pojavili epileptični napadi (konvulzije).
Health experts recommend that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV. 
Zdravstveni strokovnjaki priporočajo, naj s HIV okužene ženske v nobenem primeru ne dojijo, da se prepreči prenos HIV.
Date of first authorisation: 21 June 1996 Date of lastest renewal: 19 May 2006 
Datum zadnjega podaljšanja : 19. maj 2006
60 mg/m2/every 3 weeks) met the protocol-defined criteria for cardiac toxicity during treatment and/or follow-up. 
60 mg/m2 na vsake 3 tedne) izpolnjevalo kriterije kardiotoksičnosti po protokolu, med zdravljenjem in/ali med spremljanjem po zdravljenju.
Patients who suffer from these effects must avoid driving and operating machinery. 
Bolniki, pri katerih se pojavita ta dva neželena učinka, naj ne vozijo in ne upravljajo s stroji.
It is not known whether Caelyx is excreted in human milk. 
Ni znano, ali se zdravilo Caelyx izloča v mleko pri ljudeh.
Congestive heart failure due to cardiomyopathy may occur suddenly, without prior ECG changes and may also be encountered several weeks after discontinuation of therapy. 
Kongestivno srčno popuščanje zaradi kardiomiopatije se lahko pojavi nenadoma in brez predhodnih EKG sprememb, lahko tudi več tednov po koncu zdravljenja.
Therefore, Caelyx should not be used during pregnancy unless clearly necessary. 
Zdravila Caelyx ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.
- From a microbiological point of view, the product should be used immediately. 
- Z mikrobiološkega stališča velja, da je treba zdravilo uporabiti takoj.
Grade 4 (requires parenteral or enteral support) 
Stopnja 4 (potrebno parenteralno ali enteralno hranjenje)
Doses of bortezomib should be at least 72 hours apart. 
Med zaporednimi odmerki bortezomiba mora preteči najmanj 72 ur.
Do not use with in-line filters. 
Ne uporabljajte linij s filtri.
Temporarily stopping the infusion usually resolves these symptoms without further therapy. 
Začasna prekinitev infundiranja običajno odpravi te simptome, ne da bi bilo potrebno dodatno zdravljenje.
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the RMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed subsequent updates of the RMP. 
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnih sprejetih posodobitvah RMP.
For all patients 
Za vse bolnike
Treatment discontinuation of one or both agents due to adverse events was seen in 38% of patients. 
Zdravljenje z enim ali obema zdraviloma so zaradi pojava neželenih učinkov ukinili pri 38% bolnikov.
In patients experiencing this event, it is generally seen after two or three cycles of treatment. 
Ta učinek se pri bolnikih običajno pojavi po dveh ali treh krogih zdravljenja.
Caelyx should not be used in children and adolescents, because it is not known how the medicine will affect them. 
Zdravila Caelyx se ne sme uporabljati pri otrocih in mladostnikih, ker vpliv zdravila pri tej populaciji ni znan.
Population based analysis demonstrates that age across the range tested (21-75 years) does not significantly alter the pharmacokinetics of Caelyx. 
Populacijska analiza kaže, da starost v preskušanem razponu (21 do 75 let) bistveno ne spremeni farmakokinetike zdravila Caelyx.
Avoid intervals shorter than 10 days as medicinal product accumulation and increased toxicity cannot be ruled out. 
Presledki naj ne bodo krajši od 10 dni, ker ni mogoče izključiti kopičenja zdravila in posledične povečane toksičnosti.
If the bilirubin is > 3.0 mg/dl, the first dose is reduced by 50%. 
Če je koncentracija bilirubina > 3,0 mg/dl, prvi odmerek zmanjšajte za 50%.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2°C to 8°C. 
Če se ne uporabi takoj, čas in pogoje shranjevanja pred uporabo z lastno odgovornostjo določi uporabnik na lastno odgovornost, vendar ne sme presegati 24 ur pri temperaturi 2 °C do 8 °C.
If Caelyx comes into contact with skin or mucosa, wash immediately and thoroughly with soap and water. 
Če pride zdravilo Caelyx v stik s kožo ali sluznico, jo takoj in temeljito umijte z milom in vodo.
Other less frequently (< 5%) observed undesirable effects included hypersensitivity reactions including anaphylactic reactions. 
Med drugimi, redkejšimi (< 5%) neželenimi učinki so bile preobčutljivostne reakcije, vključno z anafilaktičnimi reakcijami.
The infusion may be given through a peripheral vein. 
Infuzija lahko teče v periferno veno.